CRISPR Therapeutics AG
CRSP
$54.13
-$0.19-0.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -64.98% | -16.64% | -141.76% | 23.37% | -62.60% |
| Total Depreciation and Amortization | -4.05% | -2.01% | -1.18% | -3.78% | -2.34% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 587.70% | 103.86% | -50.26% | -1.10% | -16.78% |
| Change in Net Operating Assets | -257.41% | -73.94% | 88.06% | -176.78% | 113.27% |
| Cash from Operations | -19.14% | -149.15% | 47.92% | -168.25% | 28.27% |
| Capital Expenditure | 83.45% | 71.43% | 65.58% | 89.66% | 80.11% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 155.54% | 79.86% | 231.43% | -230.71% | -157.24% |
| Cash from Investing | 155.14% | 79.80% | 229.93% | -233.17% | -158.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -96.54% | -56.66% | 519.54% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 584.55% | -96.54% | -56.66% | 519.54% | -102.78% |
| Foreign Exchange rate Adjustments | 3,900.00% | 472.73% | -242.62% | 256.25% | -92.86% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 81.36% | -119.84% | 152.40% | -411.81% | -321.91% |